Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice. - Wikidata - awgldk - TriplyDB

Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice.

Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice.

http://www.wikidata.org/entity/Q33338530

about

Strategically targeting MYC in cancer Cerebral metabolism following traumatic brain injury: new discoveries with implications for treatment Small-molecule inhibitors of the Myc oncoprotein The impact of small molecule binding on the energy landscape of the intrinsically disordered protein C-myc Direct inhibition of c-Myc-Max heterodimers by celastrol and celastrol-inspired triterpenoids.Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity.A high-throughput screening assay for fungicidal compounds against Cryptococcus neoformans.Role of MYC in B Cell Lymphomagenesis.c-MYC-Making Liver Sick: Role of c-MYC in Hepatic Cell Function, Homeostasis and Disease.Pathological unfoldomics of uncontrolled chaos: intrinsically disordered proteins and human diseases Therapeutic strategies to inhibit MYC In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc/Max dimerization.Therapeutic Targeting of Myc.Targeting c-Myc as a novel approach for hepatocellular carcinoma.MYC regulates the unfolded protein response and glucose and glutamine uptake in endocrine resistant breast cancer.Targeting of the MYCN protein with small molecule c-MYC inhibitors Small molecules targeting c-Myc oncogene: promising anti-cancer therapeutics A complex task? Direct modulation of transcription factors with small molecules.Arsenic trioxide sensitizes glioblastoma to a myc inhibitor.HOXB7 Is an ERα Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance.Co-targeting of Akt and Myc inhibits viability of lymphoma cells from Lck-Dlx5 mice.Strategies to Inhibit Myc and Their Clinical Applicability Structure-based Inhibitor Design for the Intrinsically Disordered Protein c-Myc.MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells Discovery of novel Myc-Max heterodimer disruptors with a three-dimensional pharmacophore model.Acidified bile acids enhance tumor progression and telomerase activity of gastric cancer in mice dependent on c-Myc expression.Wedelolactone, an Anti-inflammatory Botanical, Interrupts c-Myc Oncogenic Signaling and Synergizes with Enzalutamide to Induce Apoptosis in Prostate Cancer Cells.Acidosis decreases c-Myc oncogene expression in human lymphoma cells: a role for the proton-sensing G protein-coupled receptor TDAG8.The MYCN Protein in Health and Disease.The proto-oncogene Myc drives expression of the NK cell-activating NKp30 ligand B7-H6 in tumor cells.Therapeutic implication of concomitant chromosomal aberrations in patients with aggressive B-cell lymphomas Regulation of hepatic stellate cell proliferation and activation by glutamine metabolism Targeting MYC sensitizes malignant mesothelioma cells to PAK blockage-induced cytotoxicity.Pharmacophore identification of c-Myc inhibitor 10074-G5 Disruption of Myc-Max heterodimerization with improved cell-penetrating analogs of the small molecule 10074-G5.Human Cancer Cells Signal Their Competitive Fitness Through MYC Activity Oncogene addiction to c-MYC in myeloma cells.

P2860

Q26747745-01E0D0BE-5A82-4C6A-8555-E6CE01CF3FC1 Q27023017-5729FEED-C671-42B5-90E4-B3DD950FC755 Q27025648-8EC5FFBC-933E-44BB-B379-0518F8CC8F9E Q28481319-60EE6226-178A-463A-803C-F6AFC9E60610 Q30278518-F9346659-B5F1-4E9F-AE48-FC0C17E73814 Q33591747-8DDE7A4E-6764-4E80-B0CC-780FC3BB388B Q33595937-DBD2C5F1-D479-4F65-A279-C279084FCD4D Q33608499-DDCAEF9E-2803-47C6-8D92-32D8082E5B6E Q33608524-34F47A17-E42F-4EFD-8198-F1D3BE7D0BDC Q33909288-68725645-444C-44E9-9B0E-2711B468CAC6 Q34355349-B5381444-F076-4D8D-B96F-528C9998E7D6 Q34359903-87684FC0-939C-4D9A-8388-196A7E1F8130 Q34373258-9286A391-0B4C-4C79-80C8-9EFB0CD8C98E Q34391522-58DB3135-20D5-48DB-8468-7C7C0A713183 Q34439115-07DD0068-D8A4-4950-8D6A-4FD6974C3748 Q35173570-1B40F850-3784-4121-8E0E-98B2F4BA39B3 Q35353405-890E7004-E374-430F-99CB-DCB60928D157 Q35642431-2FE50347-9816-4A55-B4E2-F8773D4CA9E1 Q35650870-479E402E-DD7C-4F66-8F86-4CA70D17CF9E Q36029524-F9F79F70-A322-4A9A-AD88-09C44803544F Q36214162-58E5E9D0-FC64-4AA9-B000-9F72B94EEE3B Q36303678-70428964-3E9B-4117-9860-D246D12C1FD7 Q36638977-72C1B5FD-172B-46C9-8660-9AF4809254DE Q36950291-0B970EFE-8B85-47A1-80E4-C8FA25D83AA1 Q37395726-F4F70CF1-E1BE-4AD6-B30F-B3DE5F9BC8DE Q37747326-1F221008-A372-45E0-8393-A972508C2576 Q38734062-3E9916AE-4650-4E23-A16A-D64526598116 Q39072841-78ED8BA0-8FC4-4AC6-9396-540E99FC7655 Q39208675-A504CCDB-7873-4B87-B024-2F4BE79B1153 Q39397418-FDE2574E-B98A-4064-A1D8-88E00EB7A0AB Q40974570-6B16E21D-6EE7-4011-960E-A4BFC658000F Q41349258-14A29929-3446-4491-810F-F6C04003DC59 Q41547630-B6F5AC0E-CCF4-489C-8ED3-AFF669C9C0EC Q41942546-A4FA9805-3565-4CBB-9149-09515D01BBAA Q42091827-9E8A3234-8F18-4E90-88B9-2B4072500969 Q42282618-F3606A56-AD56-4681-A5C7-0BA0599BBE2C Q42409867-20106391-C8C0-4E5C-9427-71BC118372C9

P2860

Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice.

http://www.wikidata.org/entity/Q33338530

description

2008 nî lūn-bûn

@nan

2008 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Efficacy, pharmacokinetics, ti ...... oxothiazolidin-4-one, in mice.

@ast

Efficacy, pharmacokinetics, ti ...... oxothiazolidin-4-one, in mice.

@en

Efficacy, pharmacokinetics, ti ...... oxothiazolidin-4-one, in mice.

@nl

type

label

Efficacy, pharmacokinetics, ti ...... oxothiazolidin-4-one, in mice.

@ast

Efficacy, pharmacokinetics, ti ...... oxothiazolidin-4-one, in mice.

@en

Efficacy, pharmacokinetics, ti ...... oxothiazolidin-4-one, in mice.

@nl

prefLabel

Efficacy, pharmacokinetics, ti ...... oxothiazolidin-4-one, in mice.

@ast

Efficacy, pharmacokinetics, ti ...... oxothiazolidin-4-one, in mice.

@en

Efficacy, pharmacokinetics, ti ...... oxothiazolidin-4-one, in mice.

@nl

P1433

Q33338530-27CD5922-E73B-413A-950F-3A2C10E96AB1

P1476

Q33338530-99D3F4A2-4D13-4FCE-8CEE-4AAC73366E20

P2093

Q33338530-1A0C6BEE-C0AC-4A43-BB63-4445FB70BBA7

Q33338530-3FAEC7FE-9922-4434-ADA7-73B6C3C762B2

Q33338530-66B8F39E-80E1-4CF6-A475-B8C47A2BAFAB

Q33338530-C47AA682-4155-4D8E-82A9-BCD88BBE3CA2

Q33338530-C51BCFA7-38E9-4A13-B306-6D0F43FE7F87

Q33338530-F2FB02F9-6C0F-4A1D-8CC4-A7C96B461FEA

P2860

Q33338530-02830933-A643-4342-9C12-F1777EEF8BFA

Q33338530-10FB5BB2-706C-4A54-8BA1-60A09CE6F2F1

Q33338530-12A24E63-130F-4F3E-A2F0-81B879662938

Q33338530-12D7F4B9-5DBD-4A00-BE6B-84344019AC99

Q33338530-1856BDDA-C8A2-4107-9AF5-75ABF1C49FA8

Q33338530-1F342ED1-4D58-4C73-AA9A-B30C865A2947

Q33338530-2576C0D7-09E3-45E6-9E65-F273C36C290C

Q33338530-2A5DC6B2-2209-4F59-8C4E-ECF2F72E5BB6

Q33338530-2B3A4591-D132-4943-B777-73BA6EBF6484

Q33338530-2C165B6B-94CE-4C8F-B3FC-FEA560FD2832

P304

Q33338530-AA316C47-3D99-4FE9-9F6D-A2CED96696F6

P31

Q33338530-923C60FD-5BF2-41F5-BD6C-E872DC3DC71D

P356

Q33338530-B9F8FBAF-A905-4804-9748-E42D8574EB66

P433

Q33338530-48A0310E-62FA-4469-9BD9-3A986287C6E8

P478

Q33338530-0365B56E-B39F-4668-BFFA-3AACC9226396

P50

Q33338530-13F20288-722B-4AE7-B07D-0E03B2E9CDFC

P577

Q33338530-446CB3AC-3363-4130-BFEF-EBA9A48FC166

P698

Q33338530-6F2E84C7-A5F7-42EC-8784-0EC730D86AAE

P932

Q33338530-DE88FA4B-3498-47E1-9FA6-574858B8F5E4

P356

P1433

Cancer Chemotherapy and Pharmacology

P1476

Efficacy, pharmacokinetics, ti ...... oxothiazolidin-4-one, in mice.

@en

P2093

Edward V Prochownik

http://www.w3.org/2001/XMLSchema#string

Erin Joseph

http://www.w3.org/2001/XMLSchema#string

Jianxia Guo

http://www.w3.org/2001/XMLSchema#string

Julie L Eiseman

http://www.w3.org/2001/XMLSchema#string

Merrill J Egorin

http://www.w3.org/2001/XMLSchema#string

Robert A Parise

http://www.w3.org/2001/XMLSchema#string

P2860

Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts

Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription

C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer

Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo.

Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial

Mechanical thrombectomy for acute ischemic stroke: final results of the Multi MERCI trial

Guidelines for the Early Management of Adults With Ischemic Stroke

Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke

A library of gene expression signatures to illuminate normal and pathological lymphoid biology.

Improved low molecular weight Myc-Max inhibitors.

P304

615-625

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/THY.09.27

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

63

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-05-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18509642

http://www.w3.org/2001/XMLSchema#string

P932

2752825

http://www.w3.org/2001/XMLSchema#string